澳华内镜(688212) - 投资者关系活动记录表4.15

Financial Performance - Total revenue for 2023 reached 678 million CNY, representing a year-on-year growth of 52.29% [1] - Net profit attributable to shareholders was approximately 58 million CNY, with a year-on-year increase of 167.04% [1] - After excluding share-based payments, net profit attributable to shareholders was 87 million CNY [1] - Sales expenses accounted for 34.27% of operating revenue, while R&D expenses made up 21.68% [1] Revenue Breakdown - Total income of 678 million CNY comprised: - Endoscope equipment sales: 622 million CNY, accounting for 91.76% of total revenue [1] - Endoscopic diagnostic consumables: 42.57 million CNY, representing 6.28% [1] - Endoscope repair service income: 12.35 million CNY, contributing 1.82% [1] Market Insights - As of 2023, the company installed 73 mid-to-high-end models in tertiary hospitals, with 96 main units and 316 endoscopes [2] - The company aims to enhance its international market presence, viewing it as a potential growth driver [2] - The international product strategy varies by region, with a focus on high-end products in Asia and a more foundational approach in Europe [2] Service Revenue - Repair service revenue currently holds a small share of overall income due to the company's low market share, with most revenue derived from the sale of main units and endoscopes [2]